Morgan Stanley acquired 203,267 shares of NOVOSENSE (H shares) via an off-exchange derivative transaction on September 29, 2026.
Prior to the acquisition, Morgan Stanley's long position in NOVOSENSE was 979,200 shares, representing 4.87%; following the acquisition, the holding changed to 1.18 million shares, with the long position ratio rising to 5.88%.